Determinants of response and resistance to T cell-engaging therapies in multiple myeloma

Shonali Midha^{1

2}, Kenneth C Anderson^{3

4}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.
² Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.
⁴ Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.

Comment

Shonali Midha et al. Nat Rev Clin Oncol. 2023 Aug.

. 2023 Aug;20(8):505-506.

doi: 10.1038/s41571-023-00775-w.

Shonali Midha^{1

2}, Kenneth C Anderson^{3

4}

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.
² Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.
⁴ Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.

No abstract available

Comment on

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, Müller-Tidow C, Raab MS, Bahlis NJ. Friedrich MJ, et al. Cancer Cell. 2023 Apr 10;41(4):711-725.e6. doi: 10.1016/j.ccell.2023.02.008. Epub 2023 Mar 9. Cancer Cell. 2023. PMID: 36898378

1. Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell, https://doi.org/10.1016/j.ccell.2023.02.008 (2023). - DOI - PubMed
1. Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490–501 (2022). - DOI - PubMed - PMC
1. Samur, M. K. et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood 140 (Supplement 1), 2106–2107 (2022). - DOI
1. Lancman, G. et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2, 423–433 (2021). - DOI - PubMed - PMC
1. Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021). - DOI - PubMed